Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | SVP, Finance | May 18, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,267 |
Reported balance
After 2026-05-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-18 · Sale · Disposed 1,485 · Balance 118,267 F1: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. F2: Includes 67,938 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024.
F2: Includes 67,938 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 19, 2026 23:06 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,485 | $0.79 | $1,177.90 |
DisclosureSEC source: 0001193125-26-231315 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,267 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. F2 · balance_after: Includes 67,938 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:15 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 2,022 | $0.64 | $1,300.35 |
DisclosureSEC source: 0001193125-26-055445 · ownership.xml · nonDerivative · entry 3 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,752 F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F7 · balance_after: Includes 71,688 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:15 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 836 | $0.64 | $537.88 |
DisclosureSEC source: 0001193125-26-055445 · ownership.xml · nonDerivative · entry 2 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,774 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 76,376 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:15 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 611 | $0.64 | $393.12 |
DisclosureSEC source: 0001193125-26-055445 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,610 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 78,314 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:03 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 175,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001193125-26-039768 · ownership.xml · derivative · entry 2 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,500 Underlying: Common Stock · 175,500 shares Expires 2036-02-02 F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:03 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 29,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039768 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,221 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 79,720 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 01:34 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,367 | $1.33 | $1,818.11 |
DisclosureSEC source: 0001193125-25-284999 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,971 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. F2 · balance_after: Includes 50,470 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 01:00 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,722 | $1.25 | $2,157.67 |
DisclosureSEC source: 0000950170-25-109915 · ownership.xml · nonDerivative · entry 3 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,338 F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F7 · balance_after: Includes 54,220 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 01:00 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 717 | $1.25 | $898.40 |
DisclosureSEC source: 0000950170-25-109915 · ownership.xml · nonDerivative · entry 2 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,060 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 58,907 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 01:00 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 523 | $1.25 | $655.32 |
DisclosureSEC source: 0000950170-25-109915 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,777 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 60,844 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 16, 2025 Filed May 16, 2025 23:07 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,390 | $0.44 | $615.35 |
DisclosureSEC source: 0000950170-25-073825 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,300 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. F2 · balance_after: Includes 62,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 01:44 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 845 | $0.54 | $454.95 |
DisclosureSEC source: 0000950170-25-036774 · ownership.xml · nonDerivative · entry 3 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,690 F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F7 · balance_after: Includes 66,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 01:44 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 620 | $0.54 | $333.81 |
DisclosureSEC source: 0000950170-25-036774 · ownership.xml · nonDerivative · entry 2 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,535 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 67,938 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 01:44 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,017 | $0.54 | $547.55 |
DisclosureSEC source: 0000950170-25-036774 · ownership.xml · nonDerivative · entry 1 Higa Tomohiro · CIK 0002054280 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,155 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on October 15, 2022. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 69,345 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.